Figures & data
Table 1 Details of patients in the three investigational groups
Figure 1 The development of intraocular pressure (IOP) in the three groups receiving Mirtogenol, latanoprost or both, respectively, over the investigational period of 24 weeks. Mirtogenol significantly decreased IOP compared to baseline after six weeks and all later time points during the study (P < 0.05). Latanoprost alone, as well as in combination with Mirtogenol, lowered IOP after four weeks, and onwards (P < 0.05).
Table 2 The development of the diastolic blood flow velocity in response to treatment, measured using high resolution color duplex ultrasonography
Table 3 The development of the systolic blood flow velocity in response to treatment as established employing high resolution color duplex ultrasonography